Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats
Trastuzumab (TZB) is a new medicine, used to treat cancers of the breast and stomach. However, the cardiotoxic potential of this drug edges out its clinical advantages. The present study was designed to find out the effect of zingerone against trastuzumab-mediated cardiotoxicity in rats. In this stu...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/5/750 |
| _version_ | 1797599519052922880 |
|---|---|
| author | Gyas Khan Mohammad Firoz Alam Saeed Alshahrani Yosif Almoshari Abdulmajeed M. Jali Saud Alqahtani Mohammad Khalid Shehla Nasar Mir Najib Ullah Tarique Anwer |
| author_facet | Gyas Khan Mohammad Firoz Alam Saeed Alshahrani Yosif Almoshari Abdulmajeed M. Jali Saud Alqahtani Mohammad Khalid Shehla Nasar Mir Najib Ullah Tarique Anwer |
| author_sort | Gyas Khan |
| collection | DOAJ |
| description | Trastuzumab (TZB) is a new medicine, used to treat cancers of the breast and stomach. However, the cardiotoxic potential of this drug edges out its clinical advantages. The present study was designed to find out the effect of zingerone against trastuzumab-mediated cardiotoxicity in rats. In this study, five groups of rats with eight animals in each group were used. Group 1 was treated with normal saline, as a normal control (NC); Group 2 was treated with TZB (6 mg/kg/week-for five weeks) intraperitoneally as a toxic control. Groups 3 and 4 were pre-treated with zingerone (50 and 100 mg/kg, as per their body weight orally) along with five doses of TZB for five weeks, and Group 5 was treated with zingerone (100 mg/kg, body weight orally) as a control. TZB treatment showed cardiotoxicity as evidenced by increased levels of aspartate aminotransferase (AST), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), and lipid peroxidation (LPO) and decreased level of glutathione (GSH), and antioxidant enzymes such as glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-s- transferase (GST), catalase (CAT), and superoxide dismutase (SOD) activities. Zingerone pre-treatment significantly decreased the levels of AST, CK-MB, LDH, and LPO and increased GSH and antioxidant enzymes content toward their normal level. In the TZB-alone administered group, inflammatory cytokines (IL-2 and TNF-α) levels were also elevated. Pre-treatment with zingerone restored the level of IL-2 and TNF-α toward normal level. The current findings undoubtedly demonstrated zingerone’s cardioprotective nature against TZB-mediated cardiotoxicity in rats with the evidence of histopathological recall. |
| first_indexed | 2024-03-11T03:35:38Z |
| format | Article |
| id | doaj.art-8d61807a6c5b44fda223ad672b239829 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-11T03:35:38Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-8d61807a6c5b44fda223ad672b2398292023-11-18T02:03:35ZengMDPI AGJournal of Personalized Medicine2075-44262023-04-0113575010.3390/jpm13050750Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in RatsGyas Khan0Mohammad Firoz Alam1Saeed Alshahrani2Yosif Almoshari3Abdulmajeed M. Jali4Saud Alqahtani5Mohammad Khalid6Shehla Nasar Mir Najib Ullah7Tarique Anwer8Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi ArabiaDepartment of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 16278, Saudi ArabiaDepartment of Pharmacognosy, College of Pharmacy, King Khalid University, Abha 61421, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaTrastuzumab (TZB) is a new medicine, used to treat cancers of the breast and stomach. However, the cardiotoxic potential of this drug edges out its clinical advantages. The present study was designed to find out the effect of zingerone against trastuzumab-mediated cardiotoxicity in rats. In this study, five groups of rats with eight animals in each group were used. Group 1 was treated with normal saline, as a normal control (NC); Group 2 was treated with TZB (6 mg/kg/week-for five weeks) intraperitoneally as a toxic control. Groups 3 and 4 were pre-treated with zingerone (50 and 100 mg/kg, as per their body weight orally) along with five doses of TZB for five weeks, and Group 5 was treated with zingerone (100 mg/kg, body weight orally) as a control. TZB treatment showed cardiotoxicity as evidenced by increased levels of aspartate aminotransferase (AST), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), and lipid peroxidation (LPO) and decreased level of glutathione (GSH), and antioxidant enzymes such as glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-s- transferase (GST), catalase (CAT), and superoxide dismutase (SOD) activities. Zingerone pre-treatment significantly decreased the levels of AST, CK-MB, LDH, and LPO and increased GSH and antioxidant enzymes content toward their normal level. In the TZB-alone administered group, inflammatory cytokines (IL-2 and TNF-α) levels were also elevated. Pre-treatment with zingerone restored the level of IL-2 and TNF-α toward normal level. The current findings undoubtedly demonstrated zingerone’s cardioprotective nature against TZB-mediated cardiotoxicity in rats with the evidence of histopathological recall.https://www.mdpi.com/2075-4426/13/5/750zingeronetrastuzumabcardiotoxicityinterleukinIL-2 and TNF-αhistopathology |
| spellingShingle | Gyas Khan Mohammad Firoz Alam Saeed Alshahrani Yosif Almoshari Abdulmajeed M. Jali Saud Alqahtani Mohammad Khalid Shehla Nasar Mir Najib Ullah Tarique Anwer Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats Journal of Personalized Medicine zingerone trastuzumab cardiotoxicity interleukin IL-2 and TNF-α histopathology |
| title | Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats |
| title_full | Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats |
| title_fullStr | Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats |
| title_full_unstemmed | Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats |
| title_short | Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats |
| title_sort | trastuzumab mediated cardiotoxicity and its preventive intervention by zingerone through antioxidant and inflammatory pathway in rats |
| topic | zingerone trastuzumab cardiotoxicity interleukin IL-2 and TNF-α histopathology |
| url | https://www.mdpi.com/2075-4426/13/5/750 |
| work_keys_str_mv | AT gyaskhan trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT mohammadfirozalam trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT saeedalshahrani trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT yosifalmoshari trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT abdulmajeedmjali trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT saudalqahtani trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT mohammadkhalid trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT shehlanasarmirnajibullah trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats AT tariqueanwer trastuzumabmediatedcardiotoxicityanditspreventiveinterventionbyzingeronethroughantioxidantandinflammatorypathwayinrats |